NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

FLGT

Fulgent Genetics Inc

Jul 03 • 04:00PM ET

20.06

Dollar change -0.04
Percentage change -0.20	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN QGEN EXAS GH CDNA TXG ONC VCYT MYGN OMIC

| Held by: VTI IWM VXF DFAT IWN IBB VTWO FNDA SCHA DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.34	Insider Own	35.60%	Shs Outstand	30.62M	Perf Week	2.35%
Market Cap	610.70M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	0.89%	Shs Float	19.61M	Perf Month	-5.24%
Enterprise Value	294.25M	PEG	-	EPS next Q	-0.18	Inst Own	53.69%	Short Float	8.40%	Perf Quarter	13.85%
Income	-40.78M	P/S	2.09	EPS this Y	-212.57%	Inst Trans	-12.64%	Short Ratio	5.11	Perf Half Y	8.90%
Sales	292.45M	P/B	0.54	EPS next Y	-13.73%	ROA	-3.35%	Short Interest	1.65M	Perf YTD	8.61%
Book/sh	36.81	P/C	1.91	EPS next 5Y	-	ROE	-3.61%	52W High	25.11 -20.11%	Perf Year	0.10%
Cash/sh	10.52	P/FCF	-	EPS past 3/5Y	- -129.89%	ROIC	-3.60%	52W Low	14.57 37.68%	Perf 3Y	-63.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.15% 54.19%	Gross Margin	36.07%	Volatility	2.81% 2.95%	Perf 5Y	23.90%
Dividend TTM	-	EV/Sales	1.01	EPS Y/Y TTM	76.00%	Oper. Margin	-24.59%	ATR (14)	0.64	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.32	Sales Y/Y TTM	1.71%	Profit Margin	-13.94%	RSI (14)	49.02	Recom	2.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.32	EPS Q/Q	17.29%	SMA20	-1.65%	Beta	0.84	Target Price	22.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	13.92%	SMA50	0.19%	Rel Volume	0.27	Prev Close	20.10
Employees	1313	LT Debt/Eq	0.01	Earnings	May 02 BMO	SMA200	6.13%	Avg Volume	322.53K	Price	20.06
IPO	Sep 29, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	122.30% 3.09%	Trades		Volume	87,746	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Initiated	UBS	Neutral	$35
Dec-08-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $40
Nov-18-22	Initiated	Raymond James	Outperform	$45
Aug-25-22	Initiated	Credit Suisse	Outperform	$65
Feb-04-22	Resumed	Piper Sandler	Overweight	$80
Aug-05-21	Resumed	Credit Suisse	Underperform	$55
Jan-08-21	Downgrade	Credit Suisse	Neutral → Underperform	$42 → $40
Nov-24-20	Downgrade	BTIG Research	Buy → Neutral
Aug-20-20	Initiated	Oppenheimer	Outperform	$75
May-29-20	Initiated	BTIG Research	Buy	$20
Nov-05-19	Upgrade	Piper Jaffray	Neutral → Overweight
Mar-01-18	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

May-19-25 08:11AM	Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc (PR Newswire)
May-03-25 03:03AM	Fulgent Genetics Inc (FLGT) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
May-02-25 11:35PM	Q1 2025 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) +19.07%
12:27PM	Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	Loading…
07:00AM	Fulgent Reports First Quarter 2025 Financial Results (Business Wire)
Apr-21-25 04:37PM	Fulgent Genetics Inc (FLGT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Apr-10-25 04:05PM	Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025 (Business Wire) +9.64%
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha)
Mar-24-25 08:01AM	Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Mar-20-25 05:46AM	Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy (SeekingAlpha)
Mar-07-25 06:19PM	DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) -9.20%
Feb-28-25 11:30PM	Q4 2024 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
04:05PM	Loading…
Feb-06-25 04:05PM	Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 (Business Wire)
Dec-09-24 09:55AM	Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know (Zacks)
Nov-22-24 12:00PM	All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy (Zacks) +5.43%
Nov-19-24 07:16PM	Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-09-24 07:31AM	Fulgent Genetics Reports Strong Q3 2024 Results (TipRanks)
02:05AM	Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline (GuruFocus.com)
Nov-08-24 08:15AM	Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) -11.76%
07:00AM	Fulgent Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 08:00AM	Fulgent to Participate in Upcoming Conferences (Business Wire)
Nov-01-24 08:08AM	Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Oct-31-24 08:00AM	Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1 (Business Wire) +5.82%
Oct-17-24 04:05PM	Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 (Business Wire)
Aug-13-24 12:00PM	Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22% (Zacks)
Aug-02-24 08:15AM	Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates (Zacks) +6.32%
07:00AM	Loading…
07:00AM	Fulgent Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-18-24 04:36AM	Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks) -5.53%
Jul-11-24 04:05PM	Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024 (Business Wire) +5.41%
Jun-10-24 01:00AM	Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing (GlobeNewswire)
Jun-03-24 08:00AM	Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer (Business Wire)
May-24-24 08:00AM	Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting (Business Wire)
May-15-24 04:21AM	Moffitt and Fulgent Pharma partner on personalised cancer therapies (Pharmaceutical Technology)
May-14-24 04:05PM	Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics (Business Wire)
09:00AM	Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain (PR Newswire)
May-04-24 09:15AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Fulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ... (GuruFocus.com)
May-03-24 10:46PM	Q1 2024 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:34AM	Fulgent Genetics Inc (FLGT) Q1 2024 Earnings: Misses Analyst Forecasts with Wider Losses (GuruFocus.com)
08:15AM	Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Fulgent Reports First Quarter 2024 Financial Results (Business Wire)
Apr-11-24 04:05PM	Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 (Business Wire)
Feb-29-24 09:31AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 10:18PM	Q4 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) -8.14%
07:35AM	Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023 (GuruFocus.com)
07:00AM	Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-13-24 08:00AM	Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024 (Business Wire)
Feb-09-24 08:31AM	Cord Blood Registry (CBR) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing (PR Newswire)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-14-23 04:30PM	Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-05-23 09:02AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 10:26PM	Q3 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) +13.24%
04:05PM	Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting (Business Wire)
08:52AM	Fulgent Genetics Inc (FLGT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:45AM	Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Fulgent Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-25-23 08:00AM	Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting (Business Wire)
Oct-18-23 09:44AM	Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength? (Zacks)
Oct-17-23 08:00AM	Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023 (Business Wire)
Aug-05-23 08:56AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 10:08PM	Q2 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) -12.82%
08:15AM	Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Fulgent Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
Jul-18-23 08:00AM	Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023 (Business Wire)
Jun-21-23 08:00PM	FLGT: Lowering target price to $29.00 (Argus Research)
Jun-14-23 11:40AM	10 DNA Stocks Billionaires Are Loading Up On (Insider Monkey)
Jun-06-23 07:45AM	Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist (Motley Fool)
Jun-05-23 08:30AM	Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers (Business Wire)
May-23-23 09:53AM	Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics (Motley Fool)
08:20AM	2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years (Motley Fool)
May-18-23 04:05PM	Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting (Business Wire) +6.13%
May-08-23 11:15AM	3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened (TheStreet.com)
09:40AM	Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-05-23 08:15AM	Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +18.97%
07:00AM	Fulgent Reports First Quarter 2023 Financial Results (Business Wire)
Apr-26-23 08:00PM	FLGT: Rating increased to a HOLD (Argus Research)
Apr-20-23 04:05PM	Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023 (Business Wire)
Apr-16-23 02:01PM	7 Stocks to Buy to Bag Big-Time Returns in Q2 (InvestorPlace)
Apr-14-23 07:13AM	Returns Are Gaining Momentum At Fulgent Genetics (NASDAQ:FLGT) (Simply Wall St.)
06:49AM	Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength? (Zacks)
Apr-12-23 09:40AM	Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year? (Zacks)
Apr-11-23 08:00AM	Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research (PR Newswire)
Mar-27-23 09:40AM	Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-24-23 03:54PM	Fulgent Genetics (NASDAQ:FLGT) shareholders are still up 654% over 5 years despite pulling back 7.1% in the past week (Simply Wall St.)
Mar-09-23 09:40AM	Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-04-23 07:50AM	Earnings Beat: Fulgent Genetics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models (Simply Wall St.)
Mar-03-23 11:17AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 10:13AM	Q4 2022 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 08:25PM	Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
04:03PM	Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel (Business Wire)
Feb-26-23 09:05AM	This Medical Play Is Up to the Test (TheStreet.com)
Feb-23-23 04:05PM	Fulgent to Participate in the Raymond James & Associates 44th Annual Institutional Investors Conference (Business Wire)

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gao Hanlin	Chief Scientific Officer	Jun 02 '25	Sale	20.29	754	15,299	961,281	Jun 03 04:47 PM
Xie Jian	President and COO	Jun 02 '25	Sale	20.29	1,135	23,030	371,496	Jun 03 04:46 PM
Xie Jian	Officer	Jun 02 '25	Proposed Sale	20.29	1,135	23,030		Jun 02 04:49 PM
Xie Jian	President and COO	May 27 '25	Sale	20.54	1,873	38,468	372,631	May 28 04:17 PM
Gao Hanlin	Chief Scientific Officer	May 27 '25	Sale	20.54	1,039	21,339	962,035	May 28 04:16 PM
Kim Paul	CFO and Treasurer	Mar 05 '25	Buy	15.96	100,000	1,596,470	348,282	Mar 05 06:47 PM
Xie Jian	President and COO	Dec 03 '24	Sale	19.50	1,455	28,372	334,681	Dec 04 04:41 PM
Gao Hanlin	Chief Scientific Officer	Dec 03 '24	Sale	19.50	1,373	26,773	919,469	Dec 04 04:40 PM
Gao Hanlin	Officer	Dec 02 '24	Proposed Sale	19.25	1,397	26,892		Dec 02 07:10 PM
Xie Jian	Officer	Dec 02 '24	Proposed Sale	19.25	1,483	28,548		Dec 02 07:10 PM
Hsieh Ming	Chief Executive Officer	Nov 25 '24	Sale	18.26	2,227	40,663	703,711	Nov 27 05:00 PM
Gao Hanlin	Chief Scientific Officer	Nov 25 '24	Sale	18.26	497	9,075	920,842	Nov 27 05:00 PM
Xie Jian	President and COO	Nov 25 '24	Sale	18.26	689	12,581	336,136	Nov 27 05:00 PM
Xie Jian	Officer	Nov 25 '24	Proposed Sale	18.26	689	12,581		Nov 25 07:04 PM
Gao Hanlin	Officer	Nov 25 '24	Proposed Sale	18.26	497	9,075		Nov 25 07:03 PM
Hsieh Ming	Owner	Nov 25 '24	Proposed Sale	18.26	2,227	40,663		Nov 25 07:03 PM
Kim Paul	CFO and Treasurer	Sep 03 '24	Sale	21.96	1,674	36,763	209,481	Sep 05 04:21 PM
Xie Jian	President and COO	Sep 03 '24	Sale	21.96	1,594	35,006	341,170	Sep 05 04:21 PM
Gao Hanlin	Chief Scientific Officer	Sep 03 '24	Sale	21.96	1,503	33,007	923,057	Sep 05 04:20 PM
Xie Jian	Officer	Sep 03 '24	Proposed Sale	21.96	1,594	35,006		Sep 03 07:37 PM
Kim Paul	Officer	Sep 03 '24	Proposed Sale	21.96	1,674	36,763		Sep 03 07:36 PM
Gao Hanlin	Chief Scientific Officer	Aug 27 '24	Sale	22.83	563	12,855	924,560	Aug 29 06:34 PM
Xie Jian	President and COO	Aug 27 '24	Sale	22.83	715	16,326	342,764	Aug 29 06:33 PM
Hsieh Ming	Chief Executive Officer	Aug 27 '24	Sale	22.83	2,313	52,813	707,275	Aug 29 06:33 PM
Kim Paul	CFO and Treasurer	Aug 27 '24	Sale	22.83	733	16,737	211,155	Aug 29 06:33 PM
Hsieh Ming	Owner	Aug 27 '24	Proposed Sale	22.83	2,313	52,813		Aug 27 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FLGT

Fulgent Genetics Inc

Upgrade your FINVIZ experience